Gout prevalence in Veterans Affairs medical centers increased from 4.2% in 2005 to 5.8% in 2014.
Consistent with previous studies, investigators documented variation in serum urate levels over time.
This study is the first to find an association between hyperuricemia and MCD progression in adults.
Investigators examined the urate-lowering effects of febuxostat, allopurinol, and benzbromarone and their association with renal protection in CKD.
In an interview, Brian LaMoreaux, MD, MS, discusses the need for evidence-based strategies to improve outcomes for patients hospitalized with gout.
Researchers developed and validated a gout flare risk stratification tool for patients with gout who were hospitalized for nongout conditions.
Men diagnosed at age 30 years or younger had a significantly lower mean number of children than those diagnosed at age 31 to 40, 41 years or older
Researchers characterized peripheral vascular plaques that were color-coded as monosodium urate deposition by DECT, and assessed their association with MSU crystal burden in soft tissues.
Patients with asymptomatic hyperuricemia who achieved serum uric acid levels of 6.0 mg/dL or less while on urate-lowering therapy had fewer gout flare episodes, a study found.
Obesity and dyslipidemia both increase the risk of hyperuricemia.